(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Singh M et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. 2006 Vaccine pmid:16300864
Puig-Barberà J et al. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. 2004 Vaccine pmid:15530669
Del Giudice G et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. 2006 Vaccine pmid:16464520
Barnett SW et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. 1997 Vaccine pmid:9234536
Byars NE and Allison AC Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. 1987 Vaccine pmid:3499713
O'Hagan DT et al. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. 2000 Vaccine pmid:10699327
Keitel W et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. 2010 Vaccine pmid:19835829
Vesikari T et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. 2009 Vaccine pmid:19840662
Hilgers LA et al. A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. 1994 Vaccine pmid:8085385
Hilgers LA et al. A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. 1994 Vaccine pmid:8085386
Precioso AR et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. 2011 Vaccine pmid:21945258
Pariani E et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. 2011 Vaccine pmid:21974995
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Iorio AM et al. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. 2012 Vaccine pmid:22245606
Dupuis M et al. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. 1999 Vaccine pmid:10519932
Heineman TC et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. 1999 Vaccine pmid:10438046
Tsai T et al. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. 2010 Vaccine pmid:19969117
Pietrella D et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. 2010 Vaccine pmid:20038431
Fukase H et al. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. 2012 Vaccine pmid:22472791
Hatz C et al. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. 2012 Vaccine pmid:22446638
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Fox CB et al. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. 2011 Vaccine pmid:21906648
Black S et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. 2010 Vaccine pmid:20813217
de Bruijn I et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. 2007 Vaccine pmid:18063446
Tetsutani K and Ishii KJ Adjuvants in influenza vaccines. 2012 Vaccine pmid:23084848
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Parretta E et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. 2011 Vaccine pmid:21406267
Van Buynder PG et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. 2013 Vaccine pmid:23933368
Vinay TN et al. Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). 2013 Vaccine pmid:23896420
Poder A et al. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. 2014 Vaccine pmid:24252703
Dediukhina EG and Eroshin VK [Hydrocarbon biosynthesis by microorganisms]. 1973 Nov-Dec Usp Sovrem Biol pmid:4593530
PerederiÄ­ OF and Morozova RP [Squalene and sterols of rat stomach tissue and the effect of acetylsalicylic acid on their content]. 1978 Nov-Dec Ukr. Biokhim. Zh. pmid:749299
Morozova RP et al. [Separation of lipid extract from animal blood and tissues and isolation of squalene and sterols from it]. 1982 Jul-Aug Ukr. Biokhim. Zh. pmid:7135500
Vendt VP [Studies in the field of chemistry, biochemistry and photobiochemistry of sterols]. 1975 Sep-Oct Ukr Biokhim Zh pmid:1105921
Sanina OL and Datsenko ZM [Sterol composition of sarcolemma in normal rabbits and in experimental muscular dystrophy]. 1975 Nov-Dec Ukr Biokhim Zh pmid:1202710
Ihara T [Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine]. 2010 Uirusu pmid:20848866
Laursen AB [Dangerous adjuvant in swine influenza vaccine]. 2009 Ugeskr. Laeg. pmid:19866499
Bruun Laursen A [Catastrophic consequences of Pandemrix swine flu vaccine containing squalene]. 2013 Ugeskr. Laeg. pmid:23833781
Mølbak K [Squalene unlikely sinner]. 2013 Ugeskr. Laeg. pmid:23833782
Moebius FF et al. Genetic defects in postsqualene cholesterol biosynthesis. 2000 Trends Endocrinol. Metab. pmid:10707051
Siirtola A et al. Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. 2006 Transplantation pmid:16477216
Gylling H et al. Cholesterol synthesis prevails over absorption in metabolic syndrome. 2007 Transl Res pmid:17543849
Johnson WS Nonenzymic biogenetic-like olefinic cyclizations. 1967 Trans N Y Acad Sci pmid:5237390
Sunthornandh P and Ratanabanangkoon K A comparative study of three vehicles on antibody responses against elapid snake neurotoxin immunogens. 1994 Toxicon pmid:8079368
Kuroda Y et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. 2004 Toxicol. Sci. pmid:14718649
Flint OP et al. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. 1997 Toxicol. Appl. Pharmacol. pmid:9221828
Uchino T et al. Potent protecting effects of Catuaba (Anemopaegma mirandum) extracts against hydroperoxide-induced cytotoxicity. 2004 Toxicol In Vitro pmid:15046771
Yockel S and Schatz GC Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. 2012 Top Curr Chem pmid:21506003
Hayakawa K and Matsuo I Effects of PUVA therapy on skin surface lipids: skin surface lipid peroxidation in psoriasis vulgaris and its biological significance. 1986 Tokai J. Exp. Clin. Med. pmid:3672560